Exelixis, Inc.

632 articles with Exelixis, Inc.

• Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Patients With Previously Treated Advanced Hepatocellular Carcinoma

  11/12/2019

  Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received Health Canada approval of CABOMETYX® (cabozantinib) tablets for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

• Invenra Announces Expansion of Collaboration with Exelixis

  10/31/2019

  Invenra Inc. announced that it has expanded its collaboration with Exelixis, Inc.

• Exelixis Announces Third Quarter 2019 Financial Results and Provides Corporate Update

  10/30/2019

  Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2019 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.

• Exelixis to Release Third Quarter 2019 Financial Results on Wednesday, October 30, 2019

  10/16/2019

  Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT

• Calithera Biosciences Completes Patient Enrollment in Randomized CANTATA Trial of Telaglenastat and Cabozantinib in Advanced Renal Cell Carcinoma

  10/3/2019

  Top-line results expected in second half of 2020

• Exelixis to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019

  9/25/2019

  Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis management will provide a corporate overview at the 2019 Cantor Global Healthcare Conference, which is being held next week in New York. Exelixis’ presentation has been scheduled for Wednesday, October 2, 2019 at 8:55 AM EDT / 5:55 AM PDT.

• Exelixis to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019

  9/3/2019

  Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the Morgan Stanley 17th Annual Global Healthcare Conference

• Exelixis Announces Second Quarter 2019 Financial Results and Provides Corporate Update

  7/31/2019

  Exelixis, Inc. reported financial results for the second quarter of 2019 and provided an update on progress toward fulfilling its key corporate objectives, as well as discovery, development and commercial milestones.

• Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer

  7/31/2019

  Companies will partner to advance small molecules in up to six discrete projects, including three existing programs against specific predetermined targets

• Exelixis to Release Second Quarter 2019 Financial Results on Wednesday, July 31, 2019

  7/17/2019

  Exelixis, Inc. (NASDAQ: EXEL) announced today that its second quarter 2019 financial results will be released on Wednesday, July 31, 2019 after the markets close.

• Exelixis Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Patients With Advanced Solid Tumors

  7/15/2019

  Original metastatic castration-resistant prostate cancer and immunotherapy-refractory non-small cell lung cancer cohorts expanded to 80 subjects

• 

  Genentech & Exelixis' Late-Stage Melanoma Combination Falls Short in Phase III Trial

  6/21/2019

  The Phase III trial paired Exelixis and Genentech's Cotellic with a checkpoint inhibitor in advanced melanoma.

• Exelixis Announces Webcasts of Investor Conference Presentations in June 2019

  5/29/2019

  Exelixis, Inc. (Nasdaq: EXEL) today announced that the company will be presenting at the following three investor conferences in June 2019:

• Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program

  5/16/2019

  ICON-2 program targets Tissue Factor (TF) with potential broad impact in oncology

• Exelixis Announces Webcasts of Investor Conference Presentations on May 21, 2019

  5/14/2019

  Exelixis, Inc. (Nasdaq: EXEL) today announced that the company will be presenting at the following two investor conferences on Tuesday, May 21, 2019, in New York:

• Exelixis’ Collaborator Daiichi Sankyo Launches MINNEBRO® (Esaxerenone) Tablets in Japan

  5/13/2019

  First commercial sale triggers $20 million milestone payment to Exelixis

• Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma

  5/1/2019

  COSMIC-313 is the third phase 3 pivotal trial to investigate cabozantinib in combination with immune checkpoint inhibitors

• Exelixis Announces First Quarter 2019 Financial Results and Provides Corporate Update

  5/1/2019

  Total Revenue of $215.5 Million, Cabozantinib Franchise Revenue of $179.6 Million

• Exelixis’ Partner Takeda Announces Filing of New Drug Application in Japan for CABOMETYX® (Cabozantinib) for Advanced Renal Cell Carcinoma

  4/25/2019

  Regulatory submission triggers $10 million milestone payment to Exelixis under collaboration and license agreement with Takeda

• Exelixis to Release First Quarter 2019 Financial Results on Wednesday, May 1, 2019

  4/17/2019

  Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT